Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196818 | 0.89 | ALDH1A1 (0.40) | MAPK1LMNAALDH1A1NPSR1MAOB | |
| SCHEMBL2196502 | 0.88 | MAOB (0.41) | ALDH1A1MAOBMAOATSHRMAPT | |
| SCHEMBL2195971 | 0.88 | HTT (0.41) | MAPK1LMNAMAOBMAOATSHR | |
| SCHEMBL2194634 | 0.88 | TSHR (0.41) | MAPK1LMNAALDH1A1NPSR1MAOB | |
| SCHEMBL2196160 | 0.85 | MAOB (0.42) | MAOBMAOA | |
| SCHEMBL2197721 | 0.83 | HTT (0.35) | ALDH1A1MAOBMAOATSHRMAPT | |
| SCHEMBL15085518 | 0.75 | ADORA2B (0.39) | MAPK1LMNAALDH1A1TSHRPOLB | |
| SCHEMBL2195641 | 0.73 | RAB9A (0.40) | MAPK1ALDH1A1TSHRRAB9A | |
| SCHEMBL2195803 | 0.71 | LSS (0.37) | ALDH1A1RAB9A | |
| SCHEMBL2196159 | 0.70 | CYP19A1 (0.39) | LMNARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980875-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-17 | — | — | US | claimed |
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-19 | — | — | US | claimed |
| US-8481522-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-07-09 | — | — | US | claimed |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | claimed |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | MAPK1 3174/4885LMNA 2301/4885ALDH1A1 1989/4885 |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | MAPK1 3174/4885LMNA 2301/4885ALDH1A1 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.